Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Immuneering Corporation’s (Nasdaq: IMRX) SEC filings, offering a detailed view of how the clinical-stage oncology company reports its operations, financings, and key developments. Immuneering’s Class A common stock is listed on The Nasdaq Global Market, and its Exchange Act reports and current reports on Form 8‑K document material events and corporate actions related to its Deep Cyclic Inhibitor programs.
Through Forms 10‑K and 10‑Q, investors can review Immuneering’s descriptions of its business, risk factors, research and development activities, and financial condition. Current reports on Form 8‑K capture specific events such as underwritten public offerings of Class A common stock, private placements with institutional investors, entry into material definitive agreements, and announcements of clinical data from the atebimetinib program. For example, recent 8‑K filings describe the company’s securities purchase agreement with a Sanofi subsidiary, the terms of a public offering, and updated interim data from a Phase 2a trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
On Stock Titan, these filings are updated in near real time as they appear on EDGAR and are paired with AI-powered summaries that highlight the most important points. Long, technical documents are distilled to explain how financings affect Immuneering’s cash runway, what new clinical or regulatory milestones are disclosed, and how agreements such as equity distribution arrangements or clinical collaborations fit into the company’s strategy. Users can also track sections that discuss patent protection for atebimetinib, including the U.S. composition of matter patent, and references to planned pivotal Phase 3 trials and combination studies in non-small cell lung cancer.
In addition, this page allows investors to quickly locate any insider transaction reports on Form 4, proxy statements on Schedule 14A, and registration statements or prospectus supplements related to securities offerings, when available. By combining structured access to Immuneering’s filings with AI explanations, the platform helps readers understand how regulatory disclosures relate to the company’s Deep Cyclic Inhibitor pipeline, clinical development plans, and capital structure without having to parse every page manually.
Immuneering Corp (IMRX) filed a Form 144 reporting a proposed sale of 14,000 Class A shares through Fidelity Brokerage Services LLC on the NASDAQ with an approximate sale date of 09/23/2025 and an aggregate market value of $136,080.00. The filing shows the shares were acquired in two open-market purchases: 8,000 shares on 03/18/2024 (paid in cash) and 6,000 shares on 03/15/2022 (paid in cash). The filer attests there is no material nonpublic information about the issuer and no securities were sold by the filer in the past three months according to the form.
Leah R. Neufeld, the company's Chief People Officer, reported the voluntary acquisition of 11,815 shares of Immuneering Corporation Class A Common Stock on September 15, 2025 under the company’s 2021 Employee Stock Purchase Plan (ESPP). The shares were purchased at a price of $1.428 per share, which reflects the ESPP pricing feature of at least 85% of the fair market value on the enrollment date for the relevant offering period.
Following the purchase, Ms. Neufeld beneficially owned 22,544 shares. The filing notes the transaction is exempt under Rule 16b-3(c). The Form 4 was executed by an attorney-in-fact and dated September 17, 2025.
Insider purchase under ESPP: Immuneering Corp Chief Accounting Officer Mallory Morales acquired 14,497 shares of Class A Common Stock on September 15, 2025 through the companys 2021 Employee Stock Purchase Plan at a price of $1.428 per share, representing an ESPP purchase for the offering period March 16, 2025September 15, 2025. After the purchase Morales beneficially owns 27,233 shares. The filing was signed by an attorney-in-fact on September 17, 2025 and notes the transaction is exempt under Rule 16b-3(c).
Brett Matthew Hall, the company's Chief Scientific Officer and a director, reported an acquisition of 14,880 shares of Immuneering Corp Class A common stock under the company's Employee Stock Purchase Plan (ESPP). The shares were purchased on the ESPP purchase date at a price of $1.428 per share, and the reporting line shows total beneficial ownership of 374,198 shares following the transaction. The filing notes the purchase was made pursuant to the ESPP's terms, which provide for shares to be bought at no less than 85% of the fair market value determined at the enrollment date, and states the transaction is exempt under Rule 16b-3(c).
Immuneering Corp filed a Form D claiming a Regulation D exemption for a private equity offering. The Delaware corporation, based in Cambridge, Massachusetts, reports a total offering amount of $24,998,919, with $24,998,919 sold and $0 remaining to be sold. The filing lists nine investors to date and states no sales commissions or finders' fees were paid. The offering is equity and related option/warrant securities, not tied to a business combination, and the issuer does not intend the offering to last more than one year. The filing was signed by CEO Benjamin J. Zeskind.
Immuneering filed a Form S-3 registering up to $300,000,000 of securities, including Class A common stock, preferred stock, debt securities, warrants and units, available from time to time under a shelf registration. The filing also includes an equity distribution agreement prospectus supplement that covers the potential sale of up to $100,000,000 of Class A common stock under an agreement with Piper Sandler & Co., and states that those shares are included in the $300,000,000 shelf amount.
The prospectus describes the company as a clinical-stage oncology developer focused on Deep Cyclic Inhibition (DCI) and names its lead candidate atebimetinib (IMM-1-104), an oral once-daily DCI targeting the MAPK pathway. The registrant is listed on the Nasdaq Global Market under the symbol IMRX, with a reported last sale price of $3.25 per share on August 12, 2025. The prospectus incorporates risk factors and forward-looking statements, and discloses governance provisions such as a classified board, exclusive Delaware forum clauses and indemnification of directors and officers.
Immuneering Corporation is a clinical-stage oncology company focused on Deep Cyclic Inhibition of the MAPK pathway with lead candidate atebimetinib (IMM-1-104) in a Phase 1/2a trial. Interim data from the mGnP combination arm at the 320 mg once-daily dose show a 6‑month overall survival of 94% and 6‑month progression-free survival of 72% in the 34‑patient intent-to-treat cohort; among 36 response-evaluable patients at 240/320 mg, the interim disease control rate was 81% and overall response rate was 39%. Safety at the 320 mg dose was described as generally well tolerated with Grade ≥3 events ≥10% limited to Anemia 18% and Neutropenia 15%, and no Grade 5 events reported.
On the financial side, cash and cash equivalents were $26.36 million at June 30, 2025, down from $36.14 million at year-end; the company reported a net loss of $29.48 million for the six months and used $23.53 million in operating cash during the period. The company raised $13.7 million net from an ATM equity program in the six months. Management disclosed substantial doubt about the company’s ability to continue as a going concern for one year without additional funding and plans to pursue further financing and strategic options.
Immuneering Corporation announced its financial results for the quarter ended June 30, 2025 and provided operational updates, and the company furnished the full press release as Exhibit 99.1 to this Current Report. The 8-K itself does not contain the detailed financial figures or operational text; those details are included in the attached press release.
The filing explicitly states that the information is furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference into other filings except by specific reference. This document serves as a formal vehicle to make the quarter-end results and operational commentary publicly available, while the substantive metrics and narrative are contained in the exhibit.
FAQ
What is the current stock price of Immuneering (IMRX)?
What is the market cap of Immuneering (IMRX)?
